1.1. Analysis.

Comparison 1: Carboplatin/paclitaxel/topotecan versus Carboplatin/paclitaxel, Outcome 1: Overall survival (Bookman 2009)

Overall survival (Bookman 2009)
Study	Outcomes	CP (n=864)	CPG (n=864)	CPD (n=862)	CT‐CP (n=861)	CG‐CP (n=861)
Bookman 2009	Proportion OS >3 years	0.57	0.58	0.59	0.57	0.55
	No.	426	424	425	413	395
	Proportion OS >5 years	0.35	0.34	0.39	0.34	0.30
	No.	72	70	80	73	66
	Median OS, months	44.1	44.1	44.2	40.2	39.6
	Adjusted HR OS	1.00	1.006	0.952	1.051	1.114
	95%CI		0.885 to 1.144	0.836 to 1.085	0.925 to 1.194	0.982 to 1.264